tbuckley/cabot-search huggingface dataset:
High Precision Imaging of Microscopic Spread of Glioblastoma with a Targeted Ultrasensitive SERRS Molecular Imaging Probe
Authors: Ruimin Huang, Stefan Harmsen, Jason M. Samii, Hazem Karabeber, Kenneth L. Pitter, Eric C. Holland, Moritz F. Kircher
Journal: Theranostics (2016)

The dismal prognosis of patients with malignant brain tumors such as glioblastoma multiforme (GBM) is attributed mostly to their diffuse growth pattern and early microscopic tumor spread to distant regions of the brain.Because the microscopic tumor foci cannot be visualized with current imaging modalities, it remains impossible to direct treatments optimally.Here we explored the ability of integrin-targeted surface-enhanced resonance Raman spectroscopy (SERRS) nanoparticles to depict the true tumor extent in a GBM mouse model that closely mimics the pathology in humans.The recently developed SERRS-nanoparticles have a sensitivity of detection in the femtomolar range.An RGD-peptide-conjugated version for integrin-targeting (RGD-SERRS) was compared directly to its non-targeted RAD-SERRS control in the same mice via Raman multiplexing.Pre-blocking with RGD peptide before injection of RGD-SERRS nanoparticles was used to verify the specificity of integrin-targeting.In contrast to the current belief that the enhanced permeability and retention (EPR) effect results in a baseline uptake of nanoparticles regardless of their surface chemistry, integrin-targeting was shown to be highly specific, with markedly lower accumulation after pre-blocking.While the non-targeted SERRS particles enabled delineation of the main tumor, the RGD-SERRS nanoparticles afforded a major improvement in visualization of the true extent and the diffuse margins of the main tumor.This included the detection of unexpected tumor areas distant to the main tumor, tracks of migrating cells of 2-3 cells in diameter, and even isolated distant tumor cell clusters of less than 5 cells.This Raman spectroscopy-based nanoparticle-imaging technology holds promise to allow high precision visualization of the true extent of malignant brain tumors.
Abstract A23: The crosstalk between developmental endothelial locus 1 (DEL-1) and cancer stem cells in murine melanoma: A potential modality of local control
Authors: James Walker, marsha kocherla, Blake christianson, Xu qin, Jack C. yu, Babak baban
Journal: Cancer Research (2016)

Abstract Introduction: Developmental endothelial locus-1 is a homeostatic factor in the central nervous system limiting neuroinflammation and demyelination. Del-1 has an endothelial cell–restricted pattern, particularly in the embryo. However, our data now for the first time provide evidence that melanoma cells express Del-1. The relatively newly described cancer stem cells (CSCs) are tumor-initiating cells (TICs) that often survive therapy and give rise to second-line tumors by self-renewal and differentiation into multiple cell types. CSCs are proposed to persist in tumors as a distinct population and to cause relapse and metastasis by giving rise to new tumors. Therefore, development of specific therapies targeted at CSCs holds hope for improvement of survival and quality of life of cancer patients, especially those with metastatic disease. Methods: C57/BL6 mice were injected with B16F10 murine melanoma cell line (1 x 106 cells/mouse, subcutaneous). Tumor growth monitored. Controls (Group 2) received vehicle only (PBS). Once the first tumor reached 12mm in size, the mice were sacrificed and tumor cells subjected to flow-cytometry, and statistical analysis, and p-values &amp;lt;0.05 considered significant. our novel findings suggest a regulatory role for Del-1 in cancer. Alteration of inflammatory indices, apoptosis, and necroptosis with ultimate affects on tumor size and growth were all may be potentially regulated partially by a Del-1 dependent mechanism. Results: Our data showed for the first time that DEL-1 was expressed by CSCs as well as typic non stem cells tumor cells in a murine melanoma model. These DEL-1-expressing CSCs may be palying a role in tumor angiogenesis. Further, DEL-1 is capable of suppressing T lymphocyte infiltration into the tumor microenvironment. our novel findings suggest a regulatory role for Del-1 in cancer. Alteration of inflammatory indices, apoptosis, and necroptosis with ultimate affects on tumor size and growth (by affecting Cancer Stem Cells) were all may be potentially regulated partially by a Del-1 dependent mechanism. Conclusion: Our data propose a novel hypothesis that development of tumor and CSCs activity may be affected by angiogenic and regulatory nature of Del-1. Furthermore, our results suggest a therapeutic role for Del-1 as a novel modality in cancer treatment. Citation Format: James Walker, marsha kocherla, Blake christianson, Xu qin, Jack C. yu, Babak baban. The crosstalk between developmental endothelial locus 1 (DEL-1) and cancer stem cells in murine melanoma: A potential modality of local control. [abstract]. In: Proceedings of the Fourth AACR International Conference on Frontiers in Basic Cancer Research; 2015 Oct 23-26; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2016;76(3 Suppl):Abstract nr A23.
Megestrol acetate-induced adrenal suppression.
Authors: C L Loprinzi, R Fonseca, M D Jensen
Journal: Journal of Clinical Oncology (1996)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1996.14.2.689 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 8636799 Megestrol acetate-induced adrenal suppression. C L LoprinzixC L LoprinziSearch for articles by this author , R FonsecaxR FonsecaSearch for articles by this author , M D JensenxM D JensenSearch for articles by this author https://doi.org/10.1200/JCO.1996.14.2.689 PDF "Megestrol acetate-induced adrenal suppression.." Journal of Clinical Oncology, 14(2), p. 689© 1996 by American Society of Clinical Oncology
Recombinant human interleukin-3 and recombinant human granulocyte- macrophage colony-stimulating factor administered in vivo after high- dose cyclophosphamide cancer chemotherapy: effect on hematopoiesis and microenvironment in human bone marrow
Authors: A Orazi, G Cattoretti, R Schiro, S Siena, M Bregni, M Di Nicola, AM Gianni
Journal: Blood (1992)
Controversies in Management: Not for everybody
Authors: H S Jacobs
Journal: BMJ (1996)

Undiagnosed vaginal bleeding * History of endometrial atypical hyperplasia or cancer * History of breast cancer?* Hypertriglyceridaemia * Gall stones * Specific disturbances of blood clotting-for example, protein C deficiency, possibly anti- thrombin III deficiency * Vague psychiatric disturbances, particularly unrecognised depression The most important contraindication to treatment is when the patient has nothing to gain.
Furuncular Myiasis
Authors: M A Lemon, J L Aeling
Journal: New England Journal of Medicine (2000)

Figure 1 A 46-year-old woman had an enlarging, tender, draining nodule on the upper arm. Prior treatment consisting of hot compresses and a course of oral antibiotics had had no effect. The patient had no other symptoms or findings, and the results of routine blood studies were normal. She had traveled to southern Mexico six weeks earlier for an archaeological dig. During her clinic visit, a human botfly larva (Dermatobia hominis) began to emerge from the nodule (Panel A). The traditional treatment in areas where myiasis is endemic (Mexico and South and Central America) is occlusion of the furuncular punctum with pork fat to stimulate extrusion of the larva. Neither the pork-fat treatment nor surgical treatment with a cruciate excision and gentle extraction of the larva was required in this patient, because the larva (approximately 2 cm long) (Panel B) emerged from the lesion spontaneously. The female botfly deposits her eggs on the legs or body of an insect or tick. The patient presumably was infected when bitten by such an insect or tick. At the time of the bite, the botfly eggs hatch, and the larvae quickly burrow into the host's skin. Within days, the host's immune response causes the development of an inflamed furuncle. The larva has characteristic black, backward-pointing spines that anchor it in the host's skin and make removal difficult. Figure 1 A 46-year-old woman had an enlarging, tender, draining nodule on the upper arm. Prior treatment consisting of hot compresses and a course of oral antibiotics had had no effect. The patient had no other symptoms or findings, and the results of routine blood studies were normal. She had traveled to southern Mexico six weeks earlier for an archaeological dig. During her clinic visit, a human botfly larva (Dermatobia hominis) began to emerge from the nodule (Panel A). The traditional treatment in areas where myiasis is endemic (Mexico and South and Central America) is occlusion of the furuncular punctum with pork fat to stimulate extrusion of the larva. Neither the pork-fat treatment nor surgical treatment with a cruciate excision and gentle extraction of the larva was required in this patient, because the larva (approximately 2 cm long) (Panel B) emerged from the lesion spontaneously. The female botfly deposits her eggs on the legs or body of an insect or tick. The patient presumably was infected when bitten by such an insect or tick. At the time of the bite, the botfly eggs hatch, and the larvae quickly burrow into the host's skin. Within days, the host's immune response causes the development of an inflamed furuncle. The larva has characteristic black, backward-pointing spines that anchor it in the host's skin and make removal difficult. Meg A. Lemon, M.D.John L. Aeling, M.D.University of Colorado Health Sciences Center, Denver, CO 80205
Gonadotrophic Hormone Secretion from Hydatid Mole Grown in Tissue Culture&lt;xref ref-type="fn" rid="fn1"&gt;2&lt;/xref&gt;
Authors: Helen K. Waltz, William W. Tullner, Virginia J. Evans, Roy Hertz, Wilton R. Earle
Journal: JNCI Journal of the National Cancer Institute (1954)

Gonadotrophic Hormone Secretion from Hydatid Mole Grown in Tissue Culture Get access Helen K. Waltz, Helen K. Waltz Tissue Culture Section, Laboratory of Biology, and the Endocrinology Service, Research Medicine Branch, National Cancer Institute,5Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar William W. Tullner, William W. Tullner Tissue Culture Section, Laboratory of Biology, and the Endocrinology Service, Research Medicine Branch, National Cancer Institute,5Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar Virginia J. Evans, Virginia J. Evans Tissue Culture Section, Laboratory of Biology, and the Endocrinology Service, Research Medicine Branch, National Cancer Institute,5Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar Roy Hertz, Roy Hertz Tissue Culture Section, Laboratory of Biology, and the Endocrinology Service, Research Medicine Branch, National Cancer Institute,5Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar Wilton R. Earle Wilton R. Earle Tissue Culture Section, Laboratory of Biology, and the Endocrinology Service, Research Medicine Branch, National Cancer Institute,5Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 14, Issue 5, April 1954, Pages 1173–1185, https://doi.org/10.1093/jnci/14.5.1173 Published: 01 April 1954 Article history Received: 19 October 1953 Published: 01 April 1954
Final safety results of BO17704 (AVAiL): A phase III randomized study of first-line bevacizumab (Bv) and cisplatin/gemcitabine (CG) in patients (pts) with advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC)
Authors: V. Hirsh, R. Ramlau, J. von Pawel, P. Zatloukal, G. Vera, N. Leighl, J. Mezger, V. Archer, M. Reck
Journal: Journal of Clinical Oncology (2009)

8039 Background: AVAiL, an international placebo-controlled phase III trial, showed that Bv-based therapy significantly improved PFS and response rate in patients with advanced/recurrent NSCLC. This report summarizes overall safety findings from AVAiL. Methods: AVAiL randomized 1,043 patients with untreated locally advanced, metastatic or recurrent non-squamous NSCLC to C 80mg/m 2 (d1) and G 1,250mg/m 2 (d1 and d8) q3w for up to 6 cycles plus either Bv 7.5mg/kg q3w (n=331 with safety data), Bv 15mg/kg q3w (n=329) or placebo (n=326). Bv/placebo was administered until disease progression. Primary endpoint was PFS; secondary endpoints included OS, response rate, and safety. Safety was measured using NCI-CTC version 3.0 criteria for adverse events (AEs). Results: At final analysis, the median/maximum duration of Bv therapy was 4.9/28.5 mo (Bv 7.5) and 4.3/23.4 mo (Bv 15). The most common AEs overall were hematological and gastrointestinal (GI), and occurred in similar proportions of pts in the Bv and placebo arms. Grade ≥3 AEs occurred in 80%, 83%, and 77% of pts in the Bv 7.5, Bv 15 and placebo arms, respectively. The most common grade ≥3 adverse events were hematological, mainly neutropenia and thrombocytopenia. Neutropenia was reported in 43% (Bv 7.5), 40% (Bv 15) and 34% (placebo) of pts. Grade ≥3 AEs of special interest included hypertension (7%, 9% and 2%), proteinuria (2%, 3% and 0%), bleeding (4%, 5% and 2%) and hemoptysis (0.5%, 1.2% and 1.3%). The incidence of grade 5 hemoptysis was low (0.9%, 0.9% and 0% of pts, respectively). The incidence of GI perforations (&lt;1%), thromboembolic events (≤8%), CHF (≤1%) and wound healing complications (&lt;1%) was low and similar between treatment arms. The incidence of serious AEs was 39%, 45% and 36% in the Bv 7.5, Bv 15 and placebo arms, respectively. No new safety signals were reported. Conclusions: After E4599, AVAiL further demonstrated the efficacy of Bv in combination with platinum-based chemotherapy in the treatment of advanced NSCLC. Final safety data confirm the well established and manageable safety profile of Bv-based therapy in pts with advanced NSCLC. [Table: see text]
Abstract A45: Semaphorin 3C mediates glioma stem cell tumorigenicity and radioresistance
Authors: Jennifer Yu, Jianghong Man, Shoemake Jocelyn, Wu Qiulian, Jeremy Rich, Shideng Bao
Journal: Cancer Research (2015)

Abstract Purpose: Different cancer cell compartments often communicate through soluble factors to facilitate tumor growth. Glioma stem cells (GSCs) are a subset of tumor cells that resist standard therapy to contribute to disease progression. How GSCs employ a distinct secretory program to communicate with and nurture each other over the non-stem tumor cell (NSTC) population is not well defined. Methods/Materials: GSCs were enriched from patient specimens and functionally validated. We used a candidate approach to screen for secreted factors that were preferentially used by GSCs but not NSTCs. Expression was assessed by Western blot, and confirmed by immunohistochemistry and immunofluorescence in vitro and in human and mouse GBM tissues. Ligand-receptor interactions were confirmed by co-immunoprecipitation. Rac activity was assessed by Rac-GTP pulldown. Co-culture epistasis experiments were performed using knockdown and recombinant protein approaches. Glioma stem cell marker analysis (CD133, Sox2, Olig2), cell viability (ATP-dependent assays), apoptosis (TUNEL, PI/AnnexinV, cleaved caspase 3/7), self-renewal (tumorsphere formation and limiting dilution assay) and invasion (transwell migration assay) were performed. GSCs were separated in PlexinD1 hi and lo populations by FACS. Radiation (3 Gy) was delivered by Cs-137 irradiator. GSCs were used to establish orthotopic xenograft models of glioblastoma and tumor growth and animal survival were assessed. Results: We have found that GSCs preferentially secrete Sema3C and coordinately express PlexinA2/D1 receptors to activate Rac1/NFkB signaling in an autocrine and paracrine loop to promote their own survival. Importantly, Sema3C is not expressed in neural progenitor cells (NPCs) or NSTCs. Disruption of Sema3C induced apoptosis of GSCs, but not NPCs or NSTCs, and suppressed tumor growth in orthotopic models of glioblastoma. Introduction of activated Rac1 rescued the Sema3C knockdown phenotype in vivo. Furthermore, GSCs that expressed high levels of PlexinD1 receptors were more resistant to radiation, and Sema3C and PlexinD1 were upregulated after irradiation. Together, these data support that Sema3C signaling contributes to radiation resistance. Conclusions: Our study supports targeting Sema3C to break this GSC-specific autocrine/paracrine loop to improve glioblastoma treatment, potentially with a high therapeutic index. Citation Format: Jennifer Yu, Jianghong Man, Shoemake Jocelyn, Wu Qiulian, Jeremy Rich, Shideng Bao. Semaphorin 3C mediates glioma stem cell tumorigenicity and radioresistance. [abstract]. In: Proceedings of the AACR Special Conference: Advances in Brain Cancer Research; May 27-30, 2015; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2015;75(23 Suppl):Abstract nr A45.
Treatment of Psoriasis
Authors: D A Buckley, S Rogers
Journal: New England Journal of Medicine (1995)

To the Editor: The article by van der Burg et al. (March 9 issue) 1 on debulking surgery after induction chemotherapy raises some important issues.The authors state that the morbidity associated with a second operation was similar to that associated with a primary surgical procedure.This means a doubling of morbidity in those assigned to this arm of the study, and the impact on quality of life (and cost effectiveness) must be balanced against the six-month improvement in median survival rates.It will be interesting to learn the actual five-year survival rate in both arms, and we hope the authors will supply this information in the future.The authors claim that the value of primary cytoreductive surgery for ovarian cancer is beyond doubt.We would suggest otherwise.The basis of present practice derives from a small retrospective series of patients 2 and a prospective study involving 26 patients. 3 If such information were proposed as a justification for the introduction of a new chemotherapeutic agent, it is doubtful that it would be accepted.There is agreement that clearance of all macroscopic tumor in early-stage disease is curative for many patients, though in advanced disease the effect of cytoreductive surgery is not beyond doubt, since to date this practice has never been examined in a prospective study.A recent meta-analysis has indicated that primary cytoreductive surgery has a minimal, if any, effect on survival rates in advanced ovarian cancer. 4 Until a study comparing the impact of radical surgery and chemotherapy with that of chemotherapy in patients with advanced disease is completed, patients may be inappropriately subjected to radical operations without enhancing their life expectancy.
Suspected SARS patients hospitalised in French isolation units during the early SARS epidemic: The French experience
Authors: B Issartel, O Lesens, C Chidiac, Y Mouton, D Christmann, D Peyramond
Journal: Eurosurveillance (2005)

During the SARS epidemic, many patients were screened according to WHO criteria but never went on to develop SARS. In May 2003, early in the epidemic, we conducted a retrospective study to describe suspected SARS patients hospitalised in France and compared them with documented cases of patients with SARS to evaluate the screening strategy. A total of 117 patients were studied. Only 3.4% had been in close contact with a SARS patient but 73.5% came from an affected area. 67.5% had fever and respiratory symptoms on their admission to hospital. 49.6% had fever and non specific symptoms. Clinical symptoms that were significantly more common among patients with SARS were fever, myalgia, dyspnoea, and nausea or vomiting. Presumed viral fever and respiratory tract infection were the most common diagnosis. Symptoms cannot be distinguished from an early stage of SARS confirming the usefulness of the WHO case definitions in isolation decision to avoid further transmission.
Complete remission in T-cell prolymphocytic leukemia with 2-chlorodeoxyadenosine.
Authors: L Palomera, J M Domingo, J A Agulló, M Soledad Romero
Journal: Journal of Clinical Oncology (1995)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1995.13.5.1284 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 7738636 Complete remission in T-cell prolymphocytic leukemia with 2-chlorodeoxyadenosine. L PalomeraxL PalomeraSearch for articles by this author , J M DomingoxJ M DomingoSearch for articles by this author , J A AgullóxJ A AgullóSearch for articles by this author , M Soledad RomeroxM Soledad RomeroSearch for articles by this author https://doi.org/10.1200/JCO.1995.13.5.1284 PDF "Complete remission in T-cell prolymphocytic leukemia with 2-chlorodeoxyadenosine.." Journal of Clinical Oncology, 13(5), pp. 1284–1285© 1995 by American Society of Clinical Oncology
A memorable patient: Keep me in the loop
Authors: Venkita Suresh
Journal: BMJ (2006)

I am an Indian physician working in francophone Haiti (described as the poorest country in the western hemisphere) in a hospital named after Albert Schweitzer. He never visited Haiti, but his work and philosophy (reverence for all life) inspired Larimer Mellon and his wife, Gwen, to build this hospital 50 years ago to serve Haiti's rural poor. Haitians are endearing for their quiet dignity, especially when they are ill.

Leading a ward round, I greeted the next patient in her native language of Creole, and our confident and accomplished US nurse practitioner presented her “case” in English. The patient politely watched the proceedings and intervened quietly at the end of the presentation: “Now, please tell me exactly what you have told the doctor.”
Id2 reinforces TH1 differentiation and inhibits E2A to repress TFH differentiation
Authors: Laura A Shaw, Simon Bélanger, Kyla D Omilusik, Sunglim Cho, James P Scott-Browne, J Philip Nance, John Goulding, Anna Lasorella, Li-Fan Lu, Shane Crotty, Ananda W Goldrath
Journal: Nature Immunology (2016)
Tyramine infusions in bipolar illness: behavioral effects and longitudinal changes in pressor sensitivity
Authors: D Pickar, R M Cohen, D L Murphy, D Fried
Journal: American Journal of Psychiatry (1979)

Steady state intravenous tyramine dose pressor-response tests were administered to a patient with bipolar illness during depressed and hypomanic phases of her illness. The greatest tyramine sensitivity while unmedicated occurred when the patient was hypomanic, and the least sensitivity when she was depressed before her first switch. The data raise the possibility that changes in peripheral alpha-adrenergic receptor sensitivity accompany spontaneous mood cycles. Tyramine produced a replicable mood and cognitive alteration only in the infusion closest to the switch from hypomania to depression, suggesting that the CNS may be particularly susceptible to peripheral noradrenergic inputs at specific points in bipolar illness.
Death and deinstitutionalization
Authors: T J Craig, S P Lin
Journal: American Journal of Psychiatry (1981)

Death rates during a period of rapid deinstitutionalization of a state mental hospital population showed consistent reductions that were statistically significant in the elderly patient population 65 years and older. These reductions were most marked for deaths due to pneumonia; there was a moderate decrease in cardiac deaths, and essentially no change in cancer death rates. The findings suggest that through a variety of mechanisms deinstitutionalization may have had a beneficial effect on the mortality of elderly patients who remained hospitalized. Moreover, the resultant increased need for beds for these patients dramatizes the importance for program planners to base their projections for hospital use on a continuing analysis of trends rather than on static data.